vs

Side-by-side financial comparison of Amalgamated Financial Corp. (AMAL) and Axogen, Inc. (AXGN). Click either name above to swap in a different company.

Amalgamated Financial Corp. is the larger business by last-quarter revenue ($85.2M vs $61.5M, roughly 1.4× Axogen, Inc.). On growth, Axogen, Inc. posted the faster year-over-year revenue change (26.6% vs 9.4%). Amalgamated Financial Corp. produced more free cash flow last quarter ($134.4M vs $-1.4M). Over the past eight quarters, Axogen, Inc.'s revenue compounded faster (13.3% CAGR vs 4.3%).

CI Financial is a Canadian investment management company based in Toronto, Ontario. It offers investment management and wealth management services targeted to high net worth retail investors, as well as brokerage and trading services to portfolio managers and institutional investors.

Axogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering (IPO). Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is...

AMAL vs AXGN — Head-to-Head

Bigger by revenue
AMAL
AMAL
1.4× larger
AMAL
$85.2M
$61.5M
AXGN
Growing faster (revenue YoY)
AXGN
AXGN
+17.2% gap
AXGN
26.6%
9.4%
AMAL
More free cash flow
AMAL
AMAL
$135.8M more FCF
AMAL
$134.4M
$-1.4M
AXGN
Faster 2-yr revenue CAGR
AXGN
AXGN
Annualised
AXGN
13.3%
4.3%
AMAL

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
AMAL
AMAL
AXGN
AXGN
Revenue
$85.2M
$61.5M
Net Profit
$-19.6M
Gross Margin
75.2%
Operating Margin
39.0%
20.2%
Net Margin
-31.9%
Revenue YoY
9.4%
26.6%
Net Profit YoY
-410.8%
EPS (diluted)
$0.88
$-0.38

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMAL
AMAL
AXGN
AXGN
Q1 26
$61.5M
Q4 25
$85.2M
$59.9M
Q3 25
$85.6M
$60.1M
Q2 25
$80.9M
$56.7M
Q1 25
$77.0M
$48.6M
Q4 24
$77.9M
$49.4M
Q3 24
$81.0M
$48.6M
Q2 24
$78.5M
$47.9M
Net Profit
AMAL
AMAL
AXGN
AXGN
Q1 26
$-19.6M
Q4 25
$-13.2M
Q3 25
$26.8M
$708.0K
Q2 25
$26.0M
$579.0K
Q1 25
$25.0M
$-3.8M
Q4 24
$450.0K
Q3 24
$27.9M
$-1.9M
Q2 24
$26.8M
$-1.9M
Gross Margin
AMAL
AMAL
AXGN
AXGN
Q1 26
75.2%
Q4 25
74.1%
Q3 25
76.6%
Q2 25
74.2%
Q1 25
71.9%
Q4 24
76.1%
Q3 24
74.9%
Q2 24
73.8%
Operating Margin
AMAL
AMAL
AXGN
AXGN
Q1 26
20.2%
Q4 25
39.0%
-16.3%
Q3 25
42.9%
3.2%
Q2 25
43.8%
3.0%
Q1 25
45.1%
-3.4%
Q4 24
42.4%
4.1%
Q3 24
47.2%
-0.6%
Q2 24
45.6%
-0.9%
Net Margin
AMAL
AMAL
AXGN
AXGN
Q1 26
-31.9%
Q4 25
-22.0%
Q3 25
31.3%
1.2%
Q2 25
32.1%
1.0%
Q1 25
32.5%
-7.9%
Q4 24
0.9%
Q3 24
34.5%
-3.8%
Q2 24
34.1%
-4.0%
EPS (diluted)
AMAL
AMAL
AXGN
AXGN
Q1 26
$-0.38
Q4 25
$0.88
$-0.28
Q3 25
$0.88
$0.01
Q2 25
$0.84
$0.01
Q1 25
$0.81
$-0.08
Q4 24
$0.78
$-0.00
Q3 24
$0.90
$-0.04
Q2 24
$0.87
$-0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMAL
AMAL
AXGN
AXGN
Cash + ST InvestmentsLiquidity on hand
$291.2M
$82.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$794.5M
$244.8M
Total Assets
$8.9B
$289.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMAL
AMAL
AXGN
AXGN
Q1 26
$82.7M
Q4 25
$291.2M
$41.5M
Q3 25
$115.5M
$35.8M
Q2 25
$171.1M
$29.9M
Q1 25
$65.7M
$22.1M
Q4 24
$60.7M
$33.5M
Q3 24
$149.2M
$24.5M
Q2 24
$58.0M
$21.1M
Total Debt
AMAL
AMAL
AXGN
AXGN
Q1 26
Q4 25
$48.4M
Q3 25
$48.2M
Q2 25
$47.9M
Q1 25
$47.7M
Q4 24
$47.5M
Q3 24
$47.3M
Q2 24
$47.0M
Stockholders' Equity
AMAL
AMAL
AXGN
AXGN
Q1 26
$244.8M
Q4 25
$794.5M
$128.8M
Q3 25
$775.6M
$120.8M
Q2 25
$754.0M
$112.3M
Q1 25
$736.0M
$105.4M
Q4 24
$707.7M
$103.9M
Q3 24
$698.2M
$99.4M
Q2 24
$646.0M
$95.7M
Total Assets
AMAL
AMAL
AXGN
AXGN
Q1 26
$289.5M
Q4 25
$8.9B
$221.7M
Q3 25
$8.7B
$216.4M
Q2 25
$8.6B
$205.5M
Q1 25
$8.3B
$196.2M
Q4 24
$8.3B
$203.7M
Q3 24
$8.4B
$192.0M
Q2 24
$8.3B
$188.9M
Debt / Equity
AMAL
AMAL
AXGN
AXGN
Q1 26
Q4 25
0.38×
Q3 25
0.40×
Q2 25
0.43×
Q1 25
0.45×
Q4 24
0.46×
Q3 24
0.48×
Q2 24
0.49×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMAL
AMAL
AXGN
AXGN
Operating Cash FlowLast quarter
$135.8M
Free Cash FlowOCF − Capex
$134.4M
$-1.4M
FCF MarginFCF / Revenue
157.8%
-2.3%
Capex IntensityCapex / Revenue
1.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$229.4M
$9.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMAL
AMAL
AXGN
AXGN
Q1 26
Q4 25
$135.8M
$3.0M
Q3 25
$39.5M
$3.2M
Q2 25
$24.9M
$7.7M
Q1 25
$34.2M
$-13.2M
Q4 24
$124.1M
$8.7M
Q3 24
$35.8M
$3.9M
Q2 24
$28.0M
$4.2M
Free Cash Flow
AMAL
AMAL
AXGN
AXGN
Q1 26
$-1.4M
Q4 25
$134.4M
$1.8M
Q3 25
$38.3M
$1.7M
Q2 25
$24.2M
$7.0M
Q1 25
$32.5M
$-13.4M
Q4 24
$122.3M
$8.1M
Q3 24
$35.2M
$3.3M
Q2 24
$27.8M
$3.3M
FCF Margin
AMAL
AMAL
AXGN
AXGN
Q1 26
-2.3%
Q4 25
157.8%
3.0%
Q3 25
44.7%
2.8%
Q2 25
29.9%
12.4%
Q1 25
42.2%
-27.7%
Q4 24
157.0%
16.3%
Q3 24
43.4%
6.8%
Q2 24
35.4%
6.8%
Capex Intensity
AMAL
AMAL
AXGN
AXGN
Q1 26
Q4 25
1.6%
2.1%
Q3 25
1.4%
2.5%
Q2 25
0.9%
1.3%
Q1 25
2.3%
0.5%
Q4 24
2.3%
1.4%
Q3 24
0.7%
1.2%
Q2 24
0.3%
1.9%
Cash Conversion
AMAL
AMAL
AXGN
AXGN
Q1 26
Q4 25
Q3 25
1.47×
4.55×
Q2 25
0.96×
13.35×
Q1 25
1.37×
Q4 24
19.41×
Q3 24
1.28×
Q2 24
1.05×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons